Article
Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms.
European journal of haematology - 1 Mar 2014
Fu Yuewen, Schroeder Thomas, Zabelina Tatjana, Badbaran Anita, Bacher Ulrike, Kobbe Guido, Ayuk Francis, Wolschke Christine, Schnittger Susanne, Kohlmann Alexander, Haferlach Torsten, Kröger Nicolaus
Abstract excerpt
Relapse is the major cause of treatment failure after allogeneic stem-cell transplantation (AHSCT) for patients with myelodysplastic syndrome/myeloproliferative syndrome neoplasms (MDS/MPN). We evaluated the impact of molecular mutations on outcome and the value of molecular monitoring post-transplantation. We screened 45 patients with chronic myelomonocytic leukemia (n = 39 patients, including seven with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.